Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Leukemia, Myeloid, Acute 2 Triple Negative Breast Neoplasms 1 Thrombocythemia, Essential 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia 1 Cardiovascular Diseases 1 Cardiotoxicity 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Dexamethasone 363 Bortezomib 232 Lenalidomide 202 Cyclophosphamide 174 Melphalan 154 Calcium Dobesilate 107 Peripheral Blood Stem Cell Transplantation 92 fludarabine phosphate 84 Thalidomide 81 Filgrastim 71 carfilzomib 68 pomalidomide 66 Granulocyte Colony-Stimulating Factor 60 Mycophenolic Acid 59 Busulfan 57 daratumumab 55 Whole-Body Irradiation 54 Tacrolimus 51 ixazomib 50 Prednisone 50 Cyclosporine 49 fludarabine 46 Antilymphocyte Serum 35 Etoposide 30 dexamethasone acetate 29 Methotrexate 29 plerixafor 27 Radiotherapy 26 Doxorubicin 26 dexamethasone 21-phosphate 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Multiple Myeloma × Anthracyclines × Clear all

NCT02288741 2014-11-11

DSMM-II

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 3 Completed

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡